MWA
AUPH icon

Medallion Wealth Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Medallion Wealth Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-980
Closed -$7.89K – 1105
2025
Q1 		$7.89K Buy
+980
New +$7.94K ﹤0.01% 725

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Medallion Wealth Advisors's AUPH Position: Q2 2025 in Review

Medallion Wealth Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2025, closing a stake of 980 shares — an estimated $7.89K sold.

Medallion Wealth Advisors first reported a position in AUPH in Q1 2025 and held it in 1 quarter. The position peaked at $7.89K in Q1 2025. 219 funds tracked by Wall St. Rank hold AUPH as of Q2 2025.

  • Medallion Wealth Advisors reported no remaining Aurinia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Medallion Wealth Advisors sold 980 Aurinia Pharmaceuticals shares in Q2 2025, an estimated $7.89K.
  • Medallion Wealth Advisors first reported a position in Aurinia Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Medallion Wealth Advisors's Aurinia Pharmaceuticals position peaked at $7.89K in Q1 2025.
  • 219 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2025.

Based on Medallion Wealth Advisors's 13F filing for Q2 2025, filed 24 Apr 2026.